| Dr Jessica Ann Graham, DC | |
|
1002 S Dakota St, Suite 101, Milbank, SD 57252-2700 | |
| (605) 432-6676 | |
| (605) 432-6676 |
| Full Name | Dr Jessica Ann Graham |
|---|---|
| Gender | Female |
| Speciality | Chiropractic |
| Experience | 22 Years |
| Location | 1002 S Dakota St, Milbank, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588671143 | NPI | - | NPPES |
| 413330700 | Medicaid | MN | |
| 7601494 | Medicaid | SD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 984 (South Dakota) | Primary |
| Provider Name | Graham, Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225222805 PECOS PAC ID: 5597732925 Enrollment ID: O20040914001103 |
News Archive
The American Association for the Study of Liver Diseases and the Trust for America's Health issued a new report today calling for action to be taken to transform how the country deals with viral hepatitis – to help identify millions of Americans who know they are living with chronic forms of hepatitis B and C and to assure access to treatment for all who need it, to prevent even more Americans from becoming infected.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.
In one of the first studies of its kind, medical and engineering researchers have shown wearable devices that continuously monitor blood sugar provide new insights into the progression of Type 2 diabetes among at-risk Hispanic/Latino adults.
CryoPort, Inc. today announced it has closed the first round of a private placement with various accredited investors for $4.4 million. The Company obtained agreements to purchase 6,335,318 units at $0.70 per share; each unit consists of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.77 per share, pursuant to a Securities Purchase Agreement.
The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica Ann Graham, DC 1002 S Dakota St, Suite 101, Milbank, SD 57252-2700 Ph: (605) 432-6676 | Dr Jessica Ann Graham, DC 1002 S Dakota St, Suite 101, Milbank, SD 57252-2700 Ph: (605) 432-6676 |
News Archive
The American Association for the Study of Liver Diseases and the Trust for America's Health issued a new report today calling for action to be taken to transform how the country deals with viral hepatitis – to help identify millions of Americans who know they are living with chronic forms of hepatitis B and C and to assure access to treatment for all who need it, to prevent even more Americans from becoming infected.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.
In one of the first studies of its kind, medical and engineering researchers have shown wearable devices that continuously monitor blood sugar provide new insights into the progression of Type 2 diabetes among at-risk Hispanic/Latino adults.
CryoPort, Inc. today announced it has closed the first round of a private placement with various accredited investors for $4.4 million. The Company obtained agreements to purchase 6,335,318 units at $0.70 per share; each unit consists of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.77 per share, pursuant to a Securities Purchase Agreement.
The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.
› Verified 7 days ago
Alan David Bergquist, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1203 E. 4th Ave. Suite 101, Milbank, SD 57252 Phone: 605-432-9561 Fax: 605-432-9562 | |
Dr Timothy Whelan Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 235 E 2nd Ave, Milbank, SD 57252 Phone: 605-432-9070 Fax: 605-432-9070 | |
Daniel Haag, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 305 S Main St, Milbank, SD 57252 Phone: 605-432-6431 | |
Family Focus Chiropractic Chiropractor Medicare: Medicare Enrolled Practice Location: 1203 E 4th Ave Ste 101, Milbank, SD 57252 Phone: 605-432-6676 Fax: 605-432-6676 | |
Thomas Lee Hunt Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 305 S Main St, Milbank, SD 57252 Phone: 605-432-6431 | |
Terrence R Seyer, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1203 E 4th Ave Ste 101, Milbank, SD 57252 Phone: 605-432-9561 |